Read an important notice regarding the data security incident McKesson reported on August 28, 2026. Read more.
USOR 25235- Ph3 Study of Enfortumab Vedotin + Pembro in Muscle Invasive Bladder Cancer
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ARE INELIGIBLE FOR OR HAVE ELECTED NOT TO UNDERGO CYSTECTOMY
Disease Types: Bladder
Available at: Chicago, Niles, Arlington Heights